logo-loader
CytoDyn

CytoDyn anticipates near-term revenue from cell diagnostic company IncellDX

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive Investors the biotech is anticipating revenue as early as August after inking a diagnostic license and supply agreement with cell diagnostic company IncellDX Inc for the use of its PA-14 antibody.

Dr Pourhassan also addressed off-topic questions on timelines for its cancer therapy to treat metastatic triple-negative breast cancer, as well as its recent tender offer.

Quick facts: CytoDyn

Price: $0.43

Market: OTCQB
Market Cap: $156.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn sees 'strong result' in leronlimab dose escalation...

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive the biotech's HIV monotherapy dose escalating trial with its flagship drug leronlimab (PRO 140) topped expectations. Dr Pourhassan says patients receiving 525 mg achieved a 'strong result' with a 94% response rate. 

5 days, 5 hours ago

2 min read